HeartBeam Reorganizes to Accelerate Global Commercialization of 3D ECG Technology

HeartBeam Inc. (NASDAQ: BEAT) has announced a strategic reorganization aimed at accelerating execution, expanding global market reach, and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. The company is restructuring to focus on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection.

Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability, and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role. This shift is expected to enhance the company's ability to execute its commercialization strategy efficiently.

HeartBeam's strategy centers on its patented 3D ECG platform, which collects ECG signals from three non-coplanar directions and synthesizes them into a 12-lead ECG. The company plans to expand partnerships with governments, health systems, ECG manufacturers, and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment. This clearance follows an earlier FDA clearance in December 2024 for arrhythmia assessment using the 3D ECG technology.

The reorganization comes as HeartBeam aims to accelerate commercialization globally. The company holds over 20 issued patents related to its technology, which is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians can identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, redefining the future of cardiac health management.

For more details on the reorganization and HeartBeam's strategy, visit the full press release at https://ibn.fm/CTxXi. Additional information about HeartBeam's cleared indications for use can be found at https://www.heartbeam.com/indications.